The Changing Landscape of Dyslipidemia Management: Focus on PCSK9 Inhibitors

Approximately 121.5 million adults in the United States have cardiovascular disease; it is the leading cause of death in this country. The earlier patients begin to follow heart healthy lifestyles and modify risk factors, the greater their reduction in overall risk. In this activity, an expert lipidologist will review the most recent American College of Cardiology/American Heart Association guidelines on dyslipidemia, covering primary prevention as well as secondary prevention in patients with clinical atherosclerotic cardiovascular disease. He will also provide guidance regarding a patient-centered approach to the management of patients with dyslipidemia, including lifestyle management and when and how to use high-intensity statins, ezetimibe, and proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors.